Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M701046200 on March 30, 2007

J. Biol. Chem., Vol. 282, Issue 22, 16511-16520, June 1, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/22/16511    most recent
M701046200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, C.
Right arrow Articles by Bibb, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, C.
Right arrow Articles by Bibb, J. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Regulation of Protein Phosphatase Inhibitor-1 by Cyclin-dependent Kinase 5*

Chan Nguyen{ddagger}, Akinori Nishi§, Janice W. Kansy{ddagger}, Joseph Fernandez, Kanehiro Hayashi{ddagger}, Frank Gillardon||, Hugh C. Hemmings, Jr.**, Angus C. Nairn{ddagger}{ddagger}§§, and James A. Bibb{ddagger}1

From the {ddagger}Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, §Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan, Protein/DNA Technology Center and {ddagger}{ddagger}Laboratory of Cellular and Molecular Neuroscience, Rockefeller University, New York, New York 10021, ||Central Nervous System Research, Boehringer Ingelheim Pharma KG, 88397 Biberach an der Riss, Germany, **Departments of Anesthesiology and Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, and §§Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508

Inhibitor-1, the first identified endogenous inhibitor of protein phosphatase 1 (PP-1), was previously reported to be a substrate for cyclin-dependent kinase 5 (Cdk5) at Ser67. Further investigation has revealed the presence of an additional Cdk5 site identified by mass spectrometry and confirmed by site-directed mutagenesis as Ser6. Basal levels of phospho-Ser6 inhibitor-1, as detected by a phosphorylation state-specific antibody against the site, existed in specific regions of the brain and varied with age. In the striatum, basal in vivo phosphorylation and dephosphorylation of Ser6 were mediated by Cdk5, PP-2A, and PP-1, respectively. Additionally, calcineurin contributed to dephosphorylation under conditions of high Ca2+. In biochemical assays the function of Cdk5-dependent phosphorylation of inhibitor-1 at Ser6 and Ser67 was demonstrated to be an intramolecular impairment of the ability of inhibitor-1 to be dephosphorylated at Thr35; this effect was recapitulated in two systems in vivo. Dephosphorylation of inhibitor-1 at Thr35 is equivalent to inactivation of the protein, as inhibitor-1 only serves as an inhibitor of PP-1 when phosphorylated by cAMP-dependent kinase (PKA) at Thr35. Thus, inhibitor-1 serves as a critical junction between kinase- and phosphatase-signaling pathways, linking PP-1 to not only PKA and calcineurin but also Cdk5.


Received for publication, February 5, 2007 , and in revised form, March 13, 2007.

* This work was supported by Individual Pre-doctoral National Research Service Award MH072062 from the National Institutes of Health Office of Extramural Research (to C. N.); National Institute on Drug Abuse Grants DA16672 (to J. A. B.) and DA10044 (to A.C. N.); National Institute of Mental Health Grant MH67777 (to J. A. B.); NHLBI, National Institutes of Health, Grant HL077101 (to J. A. B.); and the Ella McFadden Charitable Trust Fund at the Southwestern Medical Foundation (to J. A. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Dept. of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9070. Tel.: 214-648-4168; Fax: 214-648-1293; E-mail: james.bibb{at}utsouthwestern.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement